Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus ...

Breakthroughs in tricuspid and mitral valve repair signal progress in heart treatment. BEIJING, June 3, 2025 /PRNewswire/ -- ...

Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of TRINITY Trial of LuX-Valve Plus, a ...

Aficamten was associated with improved peak oxygen uptake and a tolerable safety profile vs. metoprolol, a beta-blocker, in ...

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

Progress with transcatheter tricuspid valve replacement (TTVR) candidate devices Topaz, LuX-Valve Plus, VDyne, and Trisol for ...

An early increase in serum TTR levels on Day 28 of dosing was associated with reduced all-cause mortality (ACM) in univariate analysis, an association which persisted in multivariate analysis ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions. HEOR Analyses of Real-World Dat ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for finerenone for the treatment of adult patients with heart failure (HF ...

This analysis excluded participants with NYHA 4, or heart failure stage four because no ... patients felt better and had improved functional class.” This study did have some limitations, some ...